These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23407562)

  • 1. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer.
    Browning ET; Weickhardt AJ; Camidge DR
    J Thorac Oncol; 2013 Mar; 8(3):e21. PubMed ID: 23407562
    [No Abstract]   [Full Text] [Related]  

  • 2. Choroidal metastases responsive to crizotinib therapy in a lung adenocarcinoma patient with ALK 2p23 fusion identified by ALK immunohistochemistry.
    Feng Y; Singh AD; Lanigan C; Tubbs RR; Ma PC
    J Thorac Oncol; 2013 Dec; 8(12):e109-11. PubMed ID: 24389446
    [No Abstract]   [Full Text] [Related]  

  • 3. Is there a progression-free survival benefit of first-line crizotinib versus standard chemotherapy and second-line crizotinib in ALK-positive advanced lung adenocarcinoma? A retrospective study of Chinese patients.
    Cui S; Zhao Y; Dong L; Gu A; Xiong L; Qian J; Zhang W; Niu Y; Pan F; Jiang L
    Cancer Med; 2016 Jun; 5(6):1013-21. PubMed ID: 26880708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A; Pauwels P; Duplaquet F; D'Haene N; Weynand B; Delos M; Menon R; Heukamp LC; Thunnissen E; Ocak S
    Lung Cancer; 2016 Aug; 98():118-121. PubMed ID: 27393517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.
    Sun JM; Choi YL; Won JK; Hirsch FR; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2012 Dec; 7(12):e36-e38. PubMed ID: 23154564
    [No Abstract]   [Full Text] [Related]  

  • 6. Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.
    Toyokawa G; Takenoyama M; Watanabe S; Toyozawa R; Inamasu E; Kojo M; Shiraishi Y; Morodomi Y; Takenaka T; Hirai F; Yamaguchi M; Taguchi K; Seto T; Ichinose Y
    J Thorac Oncol; 2013 Nov; 8(11):e96-8. PubMed ID: 24128725
    [No Abstract]   [Full Text] [Related]  

  • 7. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L; Jiang P; Xu F; Zhang W; Guo L; Wu J; Zeng Y; Jiao Y; Ying J
    J Thorac Oncol; 2015 Jun; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract]   [Full Text] [Related]  

  • 8. Remarkable tumor response to crizotinib in a 14-year-old girl with ALK-positive non-small-cell lung cancer.
    Kim SJ; Kim DW; Kim TM; Lee SH; Heo DS; Bang YJ
    J Clin Oncol; 2012 Jun; 30(16):e147-50. PubMed ID: 22508824
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to chemotherapy, reexposure to crizotinib and treatment with a novel ALK inhibitor in a patient with acquired crizotinib resistance.
    Schrödl K; von Schilling C; Tufman A; Huber RM; Gamarra F
    Respiration; 2014; 88(3):262-4. PubMed ID: 25115320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.
    Zito Marino F; Morabito A; Gridelli C; Rocco G; Liguori G; De Rosa N; Botti G; Franco R
    Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):e86-e88. PubMed ID: 26990744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective crizotinib schedule for brain metastases in ALK rearrangement metastatic non-small-cell lung cancer.
    Peled N; Zach L; Liran O; Ilouze M; Bunn PA; Hirsch FR
    J Thorac Oncol; 2013 Dec; 8(12):e112-3. PubMed ID: 24389447
    [No Abstract]   [Full Text] [Related]  

  • 12. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.
    Rangachari D; Le X; Shea M; Huberman MS; VanderLaan PA; Kobayashi SS; Costa DB
    J Thorac Oncol; 2017 Nov; 12(11):e175-e177. PubMed ID: 28611010
    [No Abstract]   [Full Text] [Related]  

  • 13. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection of lung adenocarcinoma after crizotinib treatment: report of a case.
    Kaseda K; Watanabe K; Asakura K; Kazama A
    World J Surg Oncol; 2015 Feb; 13():74. PubMed ID: 25889062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.
    Maillet D; Martel-Lafay I; Arpin D; Pérol M
    J Thorac Oncol; 2013 Apr; 8(4):e30-1. PubMed ID: 23486270
    [No Abstract]   [Full Text] [Related]  

  • 16. Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
    Pilotto S; Bria E; Peretti U; Massari F; Garassino M; Pelosi G; Tortora G
    J Thorac Oncol; 2013 Dec; 8(12):e105-6. PubMed ID: 24389444
    [No Abstract]   [Full Text] [Related]  

  • 17. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.
    Yang JJ; Zhang XC; Su J; Xu CR; Zhou Q; Tian HX; Xie Z; Chen HJ; Huang YS; Jiang BY; Wang Z; Wang BC; Yang XN; Zhong WZ; Nie Q; Liao RQ; Mok TS; Wu YL
    Clin Cancer Res; 2014 Mar; 20(5):1383-92. PubMed ID: 24443522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer.
    Srivastava N; VanderLaan PA; Kelly CP; Costa DB
    J Thorac Oncol; 2013 Mar; 8(3):e23-4. PubMed ID: 23407563
    [No Abstract]   [Full Text] [Related]  

  • 19. Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma.
    Tsukita Y; Fukuhara T; Kobayashi M; Morita M; Suzuki A; Watanabe K; Noguchi T; Kurata Y; Suno M; Maemondo M
    Intern Med; 2015; 54(24):3185-8. PubMed ID: 26666609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease in patients with advanced non-small-cell lung cancer.
    Asai N; Yamaguchi E; Kubo A
    Clin Lung Cancer; 2014 May; 15(3):e33-5. PubMed ID: 24702855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.